The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Protocol amendment for ENSEMBLE study: A multicenter, randomized, phase III trial to test the superiority of consolidation irinotecan, capecitabine and oxaliplatin vs capecitabine and oxaliplatin following short course radiotherapy as total neoadjuvant therapy in patients with locally advanced rectal cancer—Changing the irinotecan dosage.
 
Koji Ando
No Relationships to Disclose
 
Jun Watanabe
Speakers' Bureau - Johnson & Johnson; Lilly; Medtronic; Takeda
Research Funding - AMCO (Inst); Medtronic (Inst); Stryker (Inst); TERUMO (Inst)
 
Yoshinori Kagawa
Consulting or Advisory Role - Lilly; Merck; Taiho Pharmaceutical
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Research Funding - Ono Pharmaceutical
 
Hideaki Bando
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Daisuke Kotani
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Seagen; Takeda
Research Funding - CMIC (Inst); CMIC (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); SERVIER (Inst); Syneos Health (Inst)
 
Yusuke Suwa
No Relationships to Disclose
 
Yujiro Nishizawa
No Relationships to Disclose
 
Yusuke Takahashi
No Relationships to Disclose
 
Nobuhisa Matsuhashi
Honoraria - Amco; Asahi Kasei; Chugai Pharma; Covidien; Daiichi Sankyo; Gunze Medical; Johnson & Johnson; Kaken Pharmaceutical; Lilly Japan; Merck KGaA; Miyarisan pharmaceutical; MSD; Ono Pharmaceutical; Stryker; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.; Viatris; Yakult Honsha
Research Funding - Abbott (Inst); Asahi Kasei (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Corporation (Inst); EPS Holdings (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Kyowa Kirin (Inst); Lilly Japan (Inst); MSD K.K (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Shift Zero (Inst); Taiho Pharmaceutical (Inst); TERUMO (Inst); Tsumura & Co. (Inst)
 
Hirokazu Suwa
No Relationships to Disclose
 
Masahiko Sugiyama
No Relationships to Disclose
 
Yukihide Kanemitsu
Honoraria - Covidien; Ethicon
 
Eiji Oki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Guardant Health
 
Mamoru Uemura
No Relationships to Disclose
 
Mitsuru Yokota
No Relationships to Disclose
 
Takahiro Tsuboyama
No Relationships to Disclose
 
Koji Oba
Honoraria - Asahi Kasei; Boehringer Ingelheim; Chugai Pharma; Diichi Sankyo; Janssen; Ono Pharmaceutical
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; MSD K.K.; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Molecular Health (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)